Global (United States, European Union and China) Prescription Drugs

Prescription Drugs Comprehensive Study by Type (Opinoids, Stimulants, Depressants), Application (Hospital, Clinic, Other), End users (Adults, Children), Drug type (Brand Drugs, Generic Drug), Distribution channel (Online, Offline) Players and Region - Global Market Outlook to 2026

Prescription Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Prescription Drugs Market?

Prescription Drugs are the drugs which are prescribed by medical practitioner. It can be obtained by presenting medical prescription.These drugs are available offline as well as online through online pharmacy. This prescription is used to control the use of drugs and practice of medicine without licence. Due to the increasing health issues the use of prescription drugs is raising globally. According to Centers for Disease Control and Prevention, 7 out of 10 adults age from 40-79 uses at least 1 prescription drug in 30 days and 1 out of 5 adults uses at least 5 prescription drugs in United States. In addition to that, the most commonly used drug among the adults aged 40 - 59 uses antidepressants, lipid-lowering drugs, and ACE inhibitors. Also, among adults aged 60- 79, most commonly used drugs are lipid-lowering drugs, anti diabetic agents, and beta blockers.

The market study is being classified by Type (Opinoids, Stimulants and Depressants), by Application (Hospital, Clinic and Other) and major geographies with country level break-up.

AbbVie (United States), Gilead Sciences (United States), GlaxoSmithKline (GSK) (United Kingdom), Amgen (United States), AstraZeneca (United Kingdom), Bristol-Myers Squibb (United States), Eli Lilly (United States), Teva (Israel), Bayer (Germany) and Novo Nordisk (Denmark) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Shire (United States), Allergan (Ireland), Pfizer (United States), Sanofi (France) and Roche (Switzerland).

The market of Prescription Drug market is Concentrated as it consists of major players. They are looking for new product launch or expansion to increase the production and meet growing demand to gain competitive advantage in upcoming years. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Prescription Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Prescription Drugs market by Type, Application and Region.

On the basis of geography, the market of Prescription Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Chronic Diseases is Fueling the Market
  • Rising Awareness for E Pharmacy is boosting the Market
  • Increasing spending on prescription drugs by consumers

Market Trend
  • Rising Investments in Research and Developments
  • Growing Expenditure towards the Health Care

Restraints
  • Stringent Government Regulations
  • Long Time Required for the Development of Prescription Drugs

Opportunities
  • Increasing usage of prescription drugs for the treatment of various diseases is boosting the market. Large pharmacies and drug wholesalers keep one or two months of medicine as a backup. However, due to sudden increase in demand for experimental treatment of COVID 19, there has been shortage of these drugs which is leading to increased manufacturing which will impact the market positively.

Challenges
  • Shortage of raw materials may hamper the market growth. The raw materials are imported from various countries. However, the majority of them are imported from china. Due to the current crisis of Corona virus, various countries have shut down their economy including China which will affect the market growth


Market Leaders and some development strategies


Food and Drug Administration has revised the format of prescription drug information which is called Package insert. It will reduce the risks of medical error and medication use. It will provide the up to date information in easy to read format. Further, it draws the attention of physician and patient as well to the important information.

Key Target Audience
Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Government Agencies and Organisations

Report Objectives / Segmentation Covered

By Type
  • Opinoids
  • Stimulants
  • Depressants
By Application
  • Hospital
  • Clinic
  • Other
By End users
  • Adults
  • Children

By Drug type
  • Brand Drugs
  • Generic Drug

By Distribution channel
  • Online
  • Offline

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Chronic Diseases is Fueling the Market
      • 3.2.2. Rising Awareness for E Pharmacy is boosting the Market
      • 3.2.3. Increasing spending on prescription drugs by consumers
    • 3.3. Market Challenges
      • 3.3.1. Shortage of raw materials may hamper the market growth. The raw materials are imported from various countries. However, the majority of them are imported from china. Due to the current crisis of Corona virus, various countries have shut down their economy including China which will affect the market growth
    • 3.4. Market Trends
      • 3.4.1. Rising Investments in Research and Developments
      • 3.4.2. Growing Expenditure towards the Health Care
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prescription Drugs, by Type, Application, End users, Drug type, Distribution channel and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Prescription Drugs (Value)
      • 5.2.1. Global Prescription Drugs by: Type (Value)
        • 5.2.1.1. Opinoids
        • 5.2.1.2. Stimulants
        • 5.2.1.3. Depressants
      • 5.2.2. Global Prescription Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Other
      • 5.2.3. Global Prescription Drugs by: End users (Value)
        • 5.2.3.1. Adults
        • 5.2.3.2. Children
      • 5.2.4. Global Prescription Drugs by: Drug type (Value)
        • 5.2.4.1. Brand Drugs
        • 5.2.4.2. Generic Drug
      • 5.2.5. Global Prescription Drugs by: Distribution channel (Value)
        • 5.2.5.1. Online
        • 5.2.5.2. Offline
      • 5.2.6. Global Prescription Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Prescription Drugs (Price)
      • 5.3.1. Global Prescription Drugs by: Type (Price)
  • 6. Prescription Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Gilead Sciences (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (GSK) (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novo Nordisk (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Prescription Drugs Sale, by Type, Application, End users, Drug type, Distribution channel and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Prescription Drugs (Value)
      • 7.2.1. Global Prescription Drugs by: Type (Value)
        • 7.2.1.1. Opinoids
        • 7.2.1.2. Stimulants
        • 7.2.1.3. Depressants
      • 7.2.2. Global Prescription Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Other
      • 7.2.3. Global Prescription Drugs by: End users (Value)
        • 7.2.3.1. Adults
        • 7.2.3.2. Children
      • 7.2.4. Global Prescription Drugs by: Drug type (Value)
        • 7.2.4.1. Brand Drugs
        • 7.2.4.2. Generic Drug
      • 7.2.5. Global Prescription Drugs by: Distribution channel (Value)
        • 7.2.5.1. Online
        • 7.2.5.2. Offline
      • 7.2.6. Global Prescription Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Prescription Drugs (Price)
      • 7.3.1. Global Prescription Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prescription Drugs: by Type(USD Million)
  • Table 2. Prescription Drugs Opinoids , by Region USD Million (2015-2020)
  • Table 3. Prescription Drugs Stimulants , by Region USD Million (2015-2020)
  • Table 4. Prescription Drugs Depressants , by Region USD Million (2015-2020)
  • Table 5. Prescription Drugs: by Application(USD Million)
  • Table 6. Prescription Drugs Hospital , by Region USD Million (2015-2020)
  • Table 7. Prescription Drugs Clinic , by Region USD Million (2015-2020)
  • Table 8. Prescription Drugs Other , by Region USD Million (2015-2020)
  • Table 9. Prescription Drugs: by End users(USD Million)
  • Table 10. Prescription Drugs Adults , by Region USD Million (2015-2020)
  • Table 11. Prescription Drugs Children , by Region USD Million (2015-2020)
  • Table 12. Prescription Drugs: by Drug type(USD Million)
  • Table 13. Prescription Drugs Brand Drugs , by Region USD Million (2015-2020)
  • Table 14. Prescription Drugs Generic Drug , by Region USD Million (2015-2020)
  • Table 15. Prescription Drugs: by Distribution channel(USD Million)
  • Table 16. Prescription Drugs Online , by Region USD Million (2015-2020)
  • Table 17. Prescription Drugs Offline , by Region USD Million (2015-2020)
  • Table 18. South America Prescription Drugs, by Country USD Million (2015-2020)
  • Table 19. South America Prescription Drugs, by Type USD Million (2015-2020)
  • Table 20. South America Prescription Drugs, by Application USD Million (2015-2020)
  • Table 21. South America Prescription Drugs, by End users USD Million (2015-2020)
  • Table 22. South America Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 23. South America Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 24. Brazil Prescription Drugs, by Type USD Million (2015-2020)
  • Table 25. Brazil Prescription Drugs, by Application USD Million (2015-2020)
  • Table 26. Brazil Prescription Drugs, by End users USD Million (2015-2020)
  • Table 27. Brazil Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 28. Brazil Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 29. Argentina Prescription Drugs, by Type USD Million (2015-2020)
  • Table 30. Argentina Prescription Drugs, by Application USD Million (2015-2020)
  • Table 31. Argentina Prescription Drugs, by End users USD Million (2015-2020)
  • Table 32. Argentina Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 33. Argentina Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 34. Rest of South America Prescription Drugs, by Type USD Million (2015-2020)
  • Table 35. Rest of South America Prescription Drugs, by Application USD Million (2015-2020)
  • Table 36. Rest of South America Prescription Drugs, by End users USD Million (2015-2020)
  • Table 37. Rest of South America Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 38. Rest of South America Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 39. Asia Pacific Prescription Drugs, by Country USD Million (2015-2020)
  • Table 40. Asia Pacific Prescription Drugs, by Type USD Million (2015-2020)
  • Table 41. Asia Pacific Prescription Drugs, by Application USD Million (2015-2020)
  • Table 42. Asia Pacific Prescription Drugs, by End users USD Million (2015-2020)
  • Table 43. Asia Pacific Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 44. Asia Pacific Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 45. China Prescription Drugs, by Type USD Million (2015-2020)
  • Table 46. China Prescription Drugs, by Application USD Million (2015-2020)
  • Table 47. China Prescription Drugs, by End users USD Million (2015-2020)
  • Table 48. China Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 49. China Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 50. Japan Prescription Drugs, by Type USD Million (2015-2020)
  • Table 51. Japan Prescription Drugs, by Application USD Million (2015-2020)
  • Table 52. Japan Prescription Drugs, by End users USD Million (2015-2020)
  • Table 53. Japan Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 54. Japan Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 55. India Prescription Drugs, by Type USD Million (2015-2020)
  • Table 56. India Prescription Drugs, by Application USD Million (2015-2020)
  • Table 57. India Prescription Drugs, by End users USD Million (2015-2020)
  • Table 58. India Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 59. India Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 60. South Korea Prescription Drugs, by Type USD Million (2015-2020)
  • Table 61. South Korea Prescription Drugs, by Application USD Million (2015-2020)
  • Table 62. South Korea Prescription Drugs, by End users USD Million (2015-2020)
  • Table 63. South Korea Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 64. South Korea Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 65. Taiwan Prescription Drugs, by Type USD Million (2015-2020)
  • Table 66. Taiwan Prescription Drugs, by Application USD Million (2015-2020)
  • Table 67. Taiwan Prescription Drugs, by End users USD Million (2015-2020)
  • Table 68. Taiwan Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 69. Taiwan Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 70. Australia Prescription Drugs, by Type USD Million (2015-2020)
  • Table 71. Australia Prescription Drugs, by Application USD Million (2015-2020)
  • Table 72. Australia Prescription Drugs, by End users USD Million (2015-2020)
  • Table 73. Australia Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 74. Australia Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 75. Rest of Asia-Pacific Prescription Drugs, by Type USD Million (2015-2020)
  • Table 76. Rest of Asia-Pacific Prescription Drugs, by Application USD Million (2015-2020)
  • Table 77. Rest of Asia-Pacific Prescription Drugs, by End users USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 80. Europe Prescription Drugs, by Country USD Million (2015-2020)
  • Table 81. Europe Prescription Drugs, by Type USD Million (2015-2020)
  • Table 82. Europe Prescription Drugs, by Application USD Million (2015-2020)
  • Table 83. Europe Prescription Drugs, by End users USD Million (2015-2020)
  • Table 84. Europe Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 85. Europe Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 86. Germany Prescription Drugs, by Type USD Million (2015-2020)
  • Table 87. Germany Prescription Drugs, by Application USD Million (2015-2020)
  • Table 88. Germany Prescription Drugs, by End users USD Million (2015-2020)
  • Table 89. Germany Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 90. Germany Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 91. France Prescription Drugs, by Type USD Million (2015-2020)
  • Table 92. France Prescription Drugs, by Application USD Million (2015-2020)
  • Table 93. France Prescription Drugs, by End users USD Million (2015-2020)
  • Table 94. France Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 95. France Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 96. Italy Prescription Drugs, by Type USD Million (2015-2020)
  • Table 97. Italy Prescription Drugs, by Application USD Million (2015-2020)
  • Table 98. Italy Prescription Drugs, by End users USD Million (2015-2020)
  • Table 99. Italy Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 100. Italy Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 101. United Kingdom Prescription Drugs, by Type USD Million (2015-2020)
  • Table 102. United Kingdom Prescription Drugs, by Application USD Million (2015-2020)
  • Table 103. United Kingdom Prescription Drugs, by End users USD Million (2015-2020)
  • Table 104. United Kingdom Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 105. United Kingdom Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 106. Netherlands Prescription Drugs, by Type USD Million (2015-2020)
  • Table 107. Netherlands Prescription Drugs, by Application USD Million (2015-2020)
  • Table 108. Netherlands Prescription Drugs, by End users USD Million (2015-2020)
  • Table 109. Netherlands Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 110. Netherlands Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 111. Rest of Europe Prescription Drugs, by Type USD Million (2015-2020)
  • Table 112. Rest of Europe Prescription Drugs, by Application USD Million (2015-2020)
  • Table 113. Rest of Europe Prescription Drugs, by End users USD Million (2015-2020)
  • Table 114. Rest of Europe Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 115. Rest of Europe Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 116. MEA Prescription Drugs, by Country USD Million (2015-2020)
  • Table 117. MEA Prescription Drugs, by Type USD Million (2015-2020)
  • Table 118. MEA Prescription Drugs, by Application USD Million (2015-2020)
  • Table 119. MEA Prescription Drugs, by End users USD Million (2015-2020)
  • Table 120. MEA Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 121. MEA Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 122. Middle East Prescription Drugs, by Type USD Million (2015-2020)
  • Table 123. Middle East Prescription Drugs, by Application USD Million (2015-2020)
  • Table 124. Middle East Prescription Drugs, by End users USD Million (2015-2020)
  • Table 125. Middle East Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 126. Middle East Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 127. Africa Prescription Drugs, by Type USD Million (2015-2020)
  • Table 128. Africa Prescription Drugs, by Application USD Million (2015-2020)
  • Table 129. Africa Prescription Drugs, by End users USD Million (2015-2020)
  • Table 130. Africa Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 131. Africa Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 132. North America Prescription Drugs, by Country USD Million (2015-2020)
  • Table 133. North America Prescription Drugs, by Type USD Million (2015-2020)
  • Table 134. North America Prescription Drugs, by Application USD Million (2015-2020)
  • Table 135. North America Prescription Drugs, by End users USD Million (2015-2020)
  • Table 136. North America Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 137. North America Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 138. United States Prescription Drugs, by Type USD Million (2015-2020)
  • Table 139. United States Prescription Drugs, by Application USD Million (2015-2020)
  • Table 140. United States Prescription Drugs, by End users USD Million (2015-2020)
  • Table 141. United States Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 142. United States Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 143. Canada Prescription Drugs, by Type USD Million (2015-2020)
  • Table 144. Canada Prescription Drugs, by Application USD Million (2015-2020)
  • Table 145. Canada Prescription Drugs, by End users USD Million (2015-2020)
  • Table 146. Canada Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 147. Canada Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 148. Mexico Prescription Drugs, by Type USD Million (2015-2020)
  • Table 149. Mexico Prescription Drugs, by Application USD Million (2015-2020)
  • Table 150. Mexico Prescription Drugs, by End users USD Million (2015-2020)
  • Table 151. Mexico Prescription Drugs, by Drug type USD Million (2015-2020)
  • Table 152. Mexico Prescription Drugs, by Distribution channel USD Million (2015-2020)
  • Table 153. Prescription Drugs: by Type(USD/Units)
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Prescription Drugs: by Type(USD Million)
  • Table 165. Prescription Drugs Opinoids , by Region USD Million (2021-2026)
  • Table 166. Prescription Drugs Stimulants , by Region USD Million (2021-2026)
  • Table 167. Prescription Drugs Depressants , by Region USD Million (2021-2026)
  • Table 168. Prescription Drugs: by Application(USD Million)
  • Table 169. Prescription Drugs Hospital , by Region USD Million (2021-2026)
  • Table 170. Prescription Drugs Clinic , by Region USD Million (2021-2026)
  • Table 171. Prescription Drugs Other , by Region USD Million (2021-2026)
  • Table 172. Prescription Drugs: by End users(USD Million)
  • Table 173. Prescription Drugs Adults , by Region USD Million (2021-2026)
  • Table 174. Prescription Drugs Children , by Region USD Million (2021-2026)
  • Table 175. Prescription Drugs: by Drug type(USD Million)
  • Table 176. Prescription Drugs Brand Drugs , by Region USD Million (2021-2026)
  • Table 177. Prescription Drugs Generic Drug , by Region USD Million (2021-2026)
  • Table 178. Prescription Drugs: by Distribution channel(USD Million)
  • Table 179. Prescription Drugs Online , by Region USD Million (2021-2026)
  • Table 180. Prescription Drugs Offline , by Region USD Million (2021-2026)
  • Table 181. South America Prescription Drugs, by Country USD Million (2021-2026)
  • Table 182. South America Prescription Drugs, by Type USD Million (2021-2026)
  • Table 183. South America Prescription Drugs, by Application USD Million (2021-2026)
  • Table 184. South America Prescription Drugs, by End users USD Million (2021-2026)
  • Table 185. South America Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 186. South America Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 187. Brazil Prescription Drugs, by Type USD Million (2021-2026)
  • Table 188. Brazil Prescription Drugs, by Application USD Million (2021-2026)
  • Table 189. Brazil Prescription Drugs, by End users USD Million (2021-2026)
  • Table 190. Brazil Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 191. Brazil Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 192. Argentina Prescription Drugs, by Type USD Million (2021-2026)
  • Table 193. Argentina Prescription Drugs, by Application USD Million (2021-2026)
  • Table 194. Argentina Prescription Drugs, by End users USD Million (2021-2026)
  • Table 195. Argentina Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 196. Argentina Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 197. Rest of South America Prescription Drugs, by Type USD Million (2021-2026)
  • Table 198. Rest of South America Prescription Drugs, by Application USD Million (2021-2026)
  • Table 199. Rest of South America Prescription Drugs, by End users USD Million (2021-2026)
  • Table 200. Rest of South America Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 201. Rest of South America Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 202. Asia Pacific Prescription Drugs, by Country USD Million (2021-2026)
  • Table 203. Asia Pacific Prescription Drugs, by Type USD Million (2021-2026)
  • Table 204. Asia Pacific Prescription Drugs, by Application USD Million (2021-2026)
  • Table 205. Asia Pacific Prescription Drugs, by End users USD Million (2021-2026)
  • Table 206. Asia Pacific Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 207. Asia Pacific Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 208. China Prescription Drugs, by Type USD Million (2021-2026)
  • Table 209. China Prescription Drugs, by Application USD Million (2021-2026)
  • Table 210. China Prescription Drugs, by End users USD Million (2021-2026)
  • Table 211. China Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 212. China Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 213. Japan Prescription Drugs, by Type USD Million (2021-2026)
  • Table 214. Japan Prescription Drugs, by Application USD Million (2021-2026)
  • Table 215. Japan Prescription Drugs, by End users USD Million (2021-2026)
  • Table 216. Japan Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 217. Japan Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 218. India Prescription Drugs, by Type USD Million (2021-2026)
  • Table 219. India Prescription Drugs, by Application USD Million (2021-2026)
  • Table 220. India Prescription Drugs, by End users USD Million (2021-2026)
  • Table 221. India Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 222. India Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 223. South Korea Prescription Drugs, by Type USD Million (2021-2026)
  • Table 224. South Korea Prescription Drugs, by Application USD Million (2021-2026)
  • Table 225. South Korea Prescription Drugs, by End users USD Million (2021-2026)
  • Table 226. South Korea Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 227. South Korea Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 228. Taiwan Prescription Drugs, by Type USD Million (2021-2026)
  • Table 229. Taiwan Prescription Drugs, by Application USD Million (2021-2026)
  • Table 230. Taiwan Prescription Drugs, by End users USD Million (2021-2026)
  • Table 231. Taiwan Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 232. Taiwan Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 233. Australia Prescription Drugs, by Type USD Million (2021-2026)
  • Table 234. Australia Prescription Drugs, by Application USD Million (2021-2026)
  • Table 235. Australia Prescription Drugs, by End users USD Million (2021-2026)
  • Table 236. Australia Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 237. Australia Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 238. Rest of Asia-Pacific Prescription Drugs, by Type USD Million (2021-2026)
  • Table 239. Rest of Asia-Pacific Prescription Drugs, by Application USD Million (2021-2026)
  • Table 240. Rest of Asia-Pacific Prescription Drugs, by End users USD Million (2021-2026)
  • Table 241. Rest of Asia-Pacific Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 242. Rest of Asia-Pacific Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 243. Europe Prescription Drugs, by Country USD Million (2021-2026)
  • Table 244. Europe Prescription Drugs, by Type USD Million (2021-2026)
  • Table 245. Europe Prescription Drugs, by Application USD Million (2021-2026)
  • Table 246. Europe Prescription Drugs, by End users USD Million (2021-2026)
  • Table 247. Europe Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 248. Europe Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 249. Germany Prescription Drugs, by Type USD Million (2021-2026)
  • Table 250. Germany Prescription Drugs, by Application USD Million (2021-2026)
  • Table 251. Germany Prescription Drugs, by End users USD Million (2021-2026)
  • Table 252. Germany Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 253. Germany Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 254. France Prescription Drugs, by Type USD Million (2021-2026)
  • Table 255. France Prescription Drugs, by Application USD Million (2021-2026)
  • Table 256. France Prescription Drugs, by End users USD Million (2021-2026)
  • Table 257. France Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 258. France Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 259. Italy Prescription Drugs, by Type USD Million (2021-2026)
  • Table 260. Italy Prescription Drugs, by Application USD Million (2021-2026)
  • Table 261. Italy Prescription Drugs, by End users USD Million (2021-2026)
  • Table 262. Italy Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 263. Italy Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 264. United Kingdom Prescription Drugs, by Type USD Million (2021-2026)
  • Table 265. United Kingdom Prescription Drugs, by Application USD Million (2021-2026)
  • Table 266. United Kingdom Prescription Drugs, by End users USD Million (2021-2026)
  • Table 267. United Kingdom Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 268. United Kingdom Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 269. Netherlands Prescription Drugs, by Type USD Million (2021-2026)
  • Table 270. Netherlands Prescription Drugs, by Application USD Million (2021-2026)
  • Table 271. Netherlands Prescription Drugs, by End users USD Million (2021-2026)
  • Table 272. Netherlands Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 273. Netherlands Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 274. Rest of Europe Prescription Drugs, by Type USD Million (2021-2026)
  • Table 275. Rest of Europe Prescription Drugs, by Application USD Million (2021-2026)
  • Table 276. Rest of Europe Prescription Drugs, by End users USD Million (2021-2026)
  • Table 277. Rest of Europe Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 278. Rest of Europe Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 279. MEA Prescription Drugs, by Country USD Million (2021-2026)
  • Table 280. MEA Prescription Drugs, by Type USD Million (2021-2026)
  • Table 281. MEA Prescription Drugs, by Application USD Million (2021-2026)
  • Table 282. MEA Prescription Drugs, by End users USD Million (2021-2026)
  • Table 283. MEA Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 284. MEA Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 285. Middle East Prescription Drugs, by Type USD Million (2021-2026)
  • Table 286. Middle East Prescription Drugs, by Application USD Million (2021-2026)
  • Table 287. Middle East Prescription Drugs, by End users USD Million (2021-2026)
  • Table 288. Middle East Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 289. Middle East Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 290. Africa Prescription Drugs, by Type USD Million (2021-2026)
  • Table 291. Africa Prescription Drugs, by Application USD Million (2021-2026)
  • Table 292. Africa Prescription Drugs, by End users USD Million (2021-2026)
  • Table 293. Africa Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 294. Africa Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 295. North America Prescription Drugs, by Country USD Million (2021-2026)
  • Table 296. North America Prescription Drugs, by Type USD Million (2021-2026)
  • Table 297. North America Prescription Drugs, by Application USD Million (2021-2026)
  • Table 298. North America Prescription Drugs, by End users USD Million (2021-2026)
  • Table 299. North America Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 300. North America Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 301. United States Prescription Drugs, by Type USD Million (2021-2026)
  • Table 302. United States Prescription Drugs, by Application USD Million (2021-2026)
  • Table 303. United States Prescription Drugs, by End users USD Million (2021-2026)
  • Table 304. United States Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 305. United States Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 306. Canada Prescription Drugs, by Type USD Million (2021-2026)
  • Table 307. Canada Prescription Drugs, by Application USD Million (2021-2026)
  • Table 308. Canada Prescription Drugs, by End users USD Million (2021-2026)
  • Table 309. Canada Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 310. Canada Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 311. Mexico Prescription Drugs, by Type USD Million (2021-2026)
  • Table 312. Mexico Prescription Drugs, by Application USD Million (2021-2026)
  • Table 313. Mexico Prescription Drugs, by End users USD Million (2021-2026)
  • Table 314. Mexico Prescription Drugs, by Drug type USD Million (2021-2026)
  • Table 315. Mexico Prescription Drugs, by Distribution channel USD Million (2021-2026)
  • Table 316. Prescription Drugs: by Type(USD/Units)
  • Table 317. Research Programs/Design for This Report
  • Table 318. Key Data Information from Secondary Sources
  • Table 319. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prescription Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Prescription Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Prescription Drugs: by End users USD Million (2015-2020)
  • Figure 7. Global Prescription Drugs: by Drug type USD Million (2015-2020)
  • Figure 8. Global Prescription Drugs: by Distribution channel USD Million (2015-2020)
  • Figure 9. South America Prescription Drugs Share (%), by Country
  • Figure 10. Asia Pacific Prescription Drugs Share (%), by Country
  • Figure 11. Europe Prescription Drugs Share (%), by Country
  • Figure 12. MEA Prescription Drugs Share (%), by Country
  • Figure 13. North America Prescription Drugs Share (%), by Country
  • Figure 14. Global Prescription Drugs: by Type USD/Units (2015-2020)
  • Figure 15. Global Prescription Drugs share by Players 2020 (%)
  • Figure 16. Global Prescription Drugs share by Players (Top 3) 2020(%)
  • Figure 17. Global Prescription Drugs share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 20. AbbVie (United States) Revenue: by Geography 2020
  • Figure 21. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 22. Gilead Sciences (United States) Revenue: by Geography 2020
  • Figure 23. GlaxoSmithKline (GSK) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline (GSK) (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 26. Amgen (United States) Revenue: by Geography 2020
  • Figure 27. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 30. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 31. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly (United States) Revenue: by Geography 2020
  • Figure 33. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva (Israel) Revenue: by Geography 2020
  • Figure 35. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer (Germany) Revenue: by Geography 2020
  • Figure 37. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 38. Novo Nordisk (Denmark) Revenue: by Geography 2020
  • Figure 39. Global Prescription Drugs: by Type USD Million (2021-2026)
  • Figure 40. Global Prescription Drugs: by Application USD Million (2021-2026)
  • Figure 41. Global Prescription Drugs: by End users USD Million (2021-2026)
  • Figure 42. Global Prescription Drugs: by Drug type USD Million (2021-2026)
  • Figure 43. Global Prescription Drugs: by Distribution channel USD Million (2021-2026)
  • Figure 44. South America Prescription Drugs Share (%), by Country
  • Figure 45. Asia Pacific Prescription Drugs Share (%), by Country
  • Figure 46. Europe Prescription Drugs Share (%), by Country
  • Figure 47. MEA Prescription Drugs Share (%), by Country
  • Figure 48. North America Prescription Drugs Share (%), by Country
  • Figure 49. Global Prescription Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • AbbVie (United States)
  • Gilead Sciences (United States)
  • GlaxoSmithKline (GSK) (United Kingdom)
  • Amgen (United States)
  • AstraZeneca (United Kingdom)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly (United States)
  • Teva (Israel)
  • Bayer (Germany)
  • Novo Nordisk (Denmark)
Additional players considered in the study are as follows:
Shire (United States) , Allergan (Ireland) , Pfizer (United States) , Sanofi (France) , Roche (Switzerland)
Select User Access Type

Key Highlights of Report


May 2021 218 Pages 70 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Prescription Drugs Quantitative research analysis
Global (United States, European Union and China) Prescription Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rising Chronic Diseases is Fueling the Market " is seen as one of major growth factors of Prescription Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global (United States, European Union and China) Prescription Drugs Report?

Have a Query? Click Here

Other Related Reports

Rheumatoid Arthritis Drug Comprehensive Study by Route of Administration (Oral, Parenteral), End-users (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharma...
$ 3750
Metabolic Disorders Drugs Comprehensive Study by Type (Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug, Amino Acid Metabolism Drug), Application (Hospital, Retail Pharmacy), Route of ...
$ 3350
Psoriasis Drug Comprehensive Study by Type (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies), Application (Packaging, Automotive, Building and Construction), Route of Administration...
$ 3450
Depression Drugs Comprehensive Study by Type (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin...
$ 3750
Ulcerative Colitis Comprehensive Study by Application (Hospital, Drugs Stores), Route of Administration (Oral, Injection), Disease level (Mild, Moderate, Severe), Ulcerative Colitis (Ulcerative proc...
$ 3650
Etoposide Comprehensive Study by Type (Etoposide for Injection, Etoposide for Oral Use), Application (Small Cell Lung Cancer, Testicular Cancer), Distribution Channel (Hospital Pharmacies, Retail Pha...
$ 3350